|
Sex
|
|
Male
|
6 (26.1%)
|
51 (24.4%)
|
0.80
|
|
Female
|
17 (73.9%)
|
158 (75.6%)
| |
|
Age (years), median (IQR)
|
81 (77.5–86.5)
|
71 (65–78)
|
< 0.01
|
|
Body weight (kg), median (IQR)
|
55 (51.7–65.3)
|
60.4 (51.0–69.1)
|
0.31
|
|
Body mass index, median (IQR)
|
23.8 (21.8–29.8)
|
25.8 (22.1–28.2)
|
0.73
|
|
Creatinine clearance (mL/min), median (IQR)
|
44.5 (38.1–47.0)
|
101.4 (79.4–125.1)
|
< 0.01
|
|
Surgical intervention
|
|
TKA
|
10 (43.5%)
|
65 (31.1%)
|
0.56
|
|
THA
|
9 (39.1%)
|
94 (45.0%)
| |
|
HFS
|
3 (13.0%)
|
25 (12.0%)
| |
|
UKA
|
1 (4.3%)
|
25 (12.0%)
| |
|
Medical history
|
|
Intracranial hemorrhage
|
1 (4.3%)
|
6 (2.9%)
|
0.52
|
|
Gastrointestinal bleeding
|
1 (4.3%)
|
4 (1.9%)
|
0.41
|
|
Venous thromboembolism
|
0
|
3 (1.4%)
|
1.00
|
|
Malignant tumor
|
1 (4.3%)
|
18 (8.6%)
|
0.70
|
|
Concomitant medication
|
|
P-glycoprotein inhibitor
|
1 (4.3%)
|
2 (1.0%)
|
0.27
|
|
Antiplatelet agent
|
3 (13.0%)
|
11 (5.3%)
|
0.15
|
|
Statin
|
9 (39.1%)
|
59 (28.2%)
|
0.33
|
|
Estrogen
|
0
|
0
|
1.00
|
|
SERM
|
0
|
6 (2.9%)
|
1.00
|
|
Adrenal corticosteroid
|
2 (8.7%)
|
8 (3.8%)
|
0.26
|
|
Antipsychotic drug
|
2 (8.7%)
|
5 (2.4%)
|
0.15
|
|
Antidepressant
|
3 (13.0%)
|
8 (3.8%)
|
0.08
|
|
Tranexamic acid
|
0
|
3 (1.4%)
|
1.00
|
